RxSight (Nasdaq:RXST) shares ticked up today on fourth-quarter results that came in ahead of the consensus forecast.
Shares of RXST rose 1.1% at $15.85 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — dipped 0.4%.
The Aliso Viejo, California-based ophthalmic medical device maker posted losses of $15.6 million. That comes to 56¢ per share on sales of $16.1 million for the three months ended Dec. 31, 2022.
RxSight’s bottom line rose by about 0.8% on sales growth of 90.9% compared to the same period last year.
Adjusted to exclude one-time items, losses per share totaled 45¢. That landed 30¢ ahead of expectations on Wall Street. Sales topped analysts’ projections, too, as they forecast $15.4 million in revenue.
In particular, sales for light adjustable lenses (LALs) boosted RxSight’s results. The company sold 9,123, marking…